SLN

Silence Therapeutics plc (NASDAQ:SLN) is a London-based biotechnology company founded in 2001 that specializes in developing RNA interference (RNAi) therapeutics. The company went public on NASDAQ in September 2020 after previously trading as SR Pharma plc before changing its name in 2007. Silence focuses on creating short interfering RNA (siRNA) molecules that can selectively silence disease-causing genes, particularly targeting rare hematological conditions, cardiovascular diseases, and metabolic disorders. The company operates through strategic partnerships with major pharmaceutical companies including AstraZeneca, Hansoh Pharmaceutical, and Mallinckrodt while advancing its proprietary pipeline of RNAi therapeutics.